- Home
- EXAS vs PCVX Comparison
EXAS vs PCVX Comparison
Compare EXAS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- PCVX
- Stock Information
- Founded
- EXAS 1995
- PCVX 2013
- Country
- EXAS United States
- PCVX United States
- Employees
- EXAS N/A
- PCVX N/A
- Industry
- EXAS Medical Specialities
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- EXAS Health Care
- PCVX Health Care
- Exchange
- EXAS Nasdaq
- PCVX Nasdaq
- Market Cap
- EXAS 12.3B
- PCVX 14.7B
- IPO Year
- EXAS N/A
- PCVX 2020
- Fundamental
- Price
- EXAS $71.05
- PCVX $106.97
- Analyst Decision
- EXAS Strong Buy
- PCVX Strong Buy
- Analyst Count
- EXAS 13
- PCVX 7
- Target Price
- EXAS $79.00
- PCVX $147.50
- AVG Volume (30 Days)
- EXAS 1.4M
- PCVX 636.4K
- Earning Date
- EXAS 11-05-2024
- PCVX 11-04-2024
- Dividend Yield
- EXAS N/A
- PCVX N/A
- EPS Growth
- EXAS N/A
- PCVX N/A
- EPS
- EXAS N/A
- PCVX N/A
- Revenue
- EXAS $2,612,011,000.00
- PCVX N/A
- Revenue This Year
- EXAS $15.53
- PCVX N/A
- Revenue Next Year
- EXAS $13.78
- PCVX N/A
- P/E Ratio
- EXAS N/A
- PCVX N/A
- Revenue Growth
- EXAS 13.54
- PCVX N/A
- 52 Week Low
- EXAS $40.62
- PCVX $46.16
- 52 Week High
- EXAS $79.62
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- EXAS 55.81
- PCVX 39.76
- Support Level
- EXAS $68.61
- PCVX $102.84
- Resistance Level
- EXAS $71.49
- PCVX $115.56
- Average True Range (ATR)
- EXAS 1.91
- PCVX 3.32
- MACD
- EXAS -0.34
- PCVX -1.41
- Stochastic Oscillator
- EXAS 50.41
- PCVX 21.55
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.